The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing ...
Hosted on MSN1mon
H.C. Wainwright maintains $80 target on Corcept Therapeutics stockO n Friday, H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback